CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial

BACKGROUND: Outcomes with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) or CHOP-like chemotherapy in peripheral T-cell lymphoma are poor. We investigated whether the regimen of gemcitabine, cisplatin, and methylprednisolone (GEM-P) was superior to CHOP as front-line therapy in...

Descripción completa

Detalles Bibliográficos
Autores principales: Gleeson, Mary, Peckitt, Clare, To, Ye Mong, Edwards, Laurice, Oates, Jacqueline, Wotherspoon, Andrew, Attygalle, Ayoma D, Zerizer, Imene, Sharma, Bhupinder, Chua, Sue, Begum, Ruwaida, Chau, Ian, Johnson, Peter, Ardeshna, Kirit M, Hawkes, Eliza A, Macheta, Marian P, Collins, Graham P, Radford, John, Forbes, Adam, Hart, Alistair, Montoto, Silvia, McKay, Pamela, Benstead, Kim, Morley, Nicholas, Kalakonda, Nagesh, Hasan, Yasmin, Turner, Deborah, Cunningham, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946805/
https://www.ncbi.nlm.nih.gov/pubmed/29703335
http://dx.doi.org/10.1016/S2352-3026(18)30039-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946805/
https://www.ncbi.nlm.nih.gov/pubmed/29703335
http://dx.doi.org/10.1016/S2352-3026(18)30039-5

Ejemplares similares